Webinar presentations: Autoantibodies as the cause of PAH; Prevalence and effect of myelofibrosis on PAH; Mast cells as the cause of pulmonary vascular remodelling in PAH; B-cell depletion with rituximab for the treatment of systemic sclerosis-associated PH; Emergency myelopoiesis contributes to immune cell exhaustion in pulmonary vascular remodelling

Webinar presentations: Therapeutic efficacy and mechanisms of Drpitor1a in PAH; SNPs for sirtuin3 and uncoupling protein2 are causal of PAH and diabetes disease severity; Mitochondrial control of metabolic, angiogenic, and hematopoietic function in PH onset and progression; Heteroplasmy of wild-type mitochondrial DNA variants causes metabolic heart disease with PH.

Webinar presentations: Update on the Human Lung RNAseq Atlas, Nathan Salomonis, USA; Unsupervised transcriptomic profiling of whole blood shows biologic heterogeneity in iPAH, Allan Lawrie, England; Cellular landscape atlas of pulmonary endarterectomy tissue using single cell RNAseq, Peiran Yang, China; Single cell RNAseq identifies cellular abnormalities in rodent models of PH, Jason Hong, USA.

Webinar presentations: Mechanosensitive cation channels in the pulmonary vascular wall in PAH; Proton exchangers in pulmonary smooth muscle cells in PAH; Pathophysiologic role of mutant potassium channels in pulmonary hypertension; TRPV4 activity in lung microvascular endothelial cells in PAH

Webinar presentations: Clinical challenges in developing drug therapies for children with PH, Challenges related to drug approval for children with PH – regulatory perspective, Challenges facing pharmaceuticals in drug development for paediatric PH, Utility of paediatric registries for the characterization of pulmonary hypertensive phenotypes.

Webinar presentations: ADVANCE Trial – Ralinepag – prostacyclin receptor agonist, Fernando Torres; Sotatercept phase 2 and phase 3 trials, Marc Humbert; TORREY Trial – Inhaled seralutinib (PDGFR, CSFIR, c-Kit inhibitor), Robert Frantz; VIPAH-PRN Trial – Vardenafil inhaled phosphodiesterase type-5 inhibitor powder, Veronica Franco

Webinar presentations: Pro-con: All patients should have balloon pulmonary angioplasty before being referred for pulmonary endarterectomy, Hiromi Matsubara (PRO) & Marcin Kurzyna (CON); Pro-con: Pulmonary hypertension recurs after pulmonary endarterectomy in most patients, Irene Lang (PRO) & Timothy Fernandes (CON)

Webinar presentations: Improving accuracy in prognosis in PAH Prognostic Scoring Systems – REVEAL 2.0 onwards, Raymond Benza; Integration of mutational profile into PAH Risk Calculators for better assessment of prognosis, Eric Austin; Integration of biomarkers into PAH Risk Calculators for better assessment of prognosis, Anna Hemnes